Clearpoint Neuro, Inc. (CLPT)
AI stock analysis · as of Jun 17, 2026
Loading microstructure…
ClearPoint Neuro is a small-cap commercial-stage neurosurgical device company combining MRI-guided navigation hardware/disposables with a fast-growing biologics drug-delivery services arm (SmartFlow cannula, 60+ pharma partners), and just bolted on IRRAS/IRRAflow (Nov 2025) to enter neurocritical care. The core investment question is whether the disposables-plus-drug-delivery flywheel can scale to profitability before cash burn and the leveraged TPC note facility force dilution, and whether partner FDA approvals (e.g., the June 2026 catalyst that drove a 33% pop) translate into durable royalty/disposable revenue.
valuationExpensive on absolute multiples (P/S 13x, P/B 28x, negative EV/EBITDA and FCF yield -2.2%) but defensible on PEG 0.61 if 30%+ growth and drug-delivery optionality compound — fair-to-rich for a story stock, not cheap.
This analysis is from Jun 17, 2026. Want the latest on CLPT, plus the ability to generate fresh research on demand?
Every call we make is tracked publicly against what the stock actually did. See the track record →
One free AI report every day. No card required.
Bull case
- · Revenue accelerating: FY2025 revenue $37.0M, +17.8% YoY reported with key_metrics revenue_growth of 42.9%, on gross margins expanding to 61.4% — consistent with a high-margin disposables/services mix taking hold.
- · Drug-delivery optionality is real: SmartFlow received De Novo FDA authorization in 2024 for AADC gene therapy (first commercial precedent), and the June 2026 partner FDA approval catalyst (likely uniQure) validates ClearPoint as the de facto delivery platform for CNS gene therapies.
- · IRRAS acquisition expands TAM into EVD/ICP monitoring with the same razor/razor-blade disposable model, and ClearPoint Navigation Software v3.0 (2025) + SmartFrame OR (2024) extend reach outside the MRI suite to a much broader hospital base.
- · Strong analyst conviction: 3 analysts, all strong_buy, mean target $22 (24% upside), high $30; PEG of 0.61 suggests growth is not fully priced relative to forward expectations.
- · Elevated short interest (16.4% of float, 7.8 days to cover) sets up squeeze potential on any additional partner FDA approval or earnings beat.
- · Sticky installed base: each capital placement seeds recurring disposable revenue; combined ClearPoint + IRRAflow sales force creates cross-sell leverage.
Bear case
- · Never profitable since 1998: FY2025 net loss widened to -$25.5M from -$18.9M, net margin -69%, operating margin -70%, and FCF -$24.4M — burn is accelerating, not narrowing.
- · Balance sheet is tight and leveraged: $45.9M cash vs $58.2M debt under the 2025 TPC/Oberland note facility with operational covenants; debt/equity of 337% and P/B of 28x signal a thin equity cushion and likely future dilution.
- · Customer concentration: PTC Therapeutics ~15% of biologics revenue in 2025; biologics growth is entirely dependent on third-party pharma trial success and reimbursement, which ClearPoint does not control.
- · Valuation is rich on absolute basis: P/S 13x, P/B 28x, EV/EBITDA negative, forward P/E -18.8x — pricing implies sustained 30%+ growth and a clear path to profitability that is not yet demonstrated (Q1 2026 missed revenue estimates per news).
- · Competitive pressure from Medtronic, Brainlab, Integra, and B. Braun — all materially better capitalized in both navigation and EVD/ICP markets.
- · Integration risk on IRRAS: managing two platforms, single-facility manufacturing in Carlsbad and San Diego, and single-source suppliers create execution and supply concentration risk.
Catalysts
- · Next earnings on 2026-08-11 — watch for revenue reacceleration, IRRAflow contribution, and updated cash runway/guidance.
- · Additional partner FDA approvals using SmartFlow (gene therapy pipeline of 60+ partners) — each clearance could trigger a re-rating similar to the June 2026 33% move.
- · IRRAflow new indication clearances (subdural hematoma, oncology, intracranial drug delivery) expanding addressable market.
- · Short squeeze potential: 16.4% short float and 7.83 days to cover make positive surprises self-reinforcing.
- · IRRAS integration milestones / synergy realization commentary on subsequent calls.
- · Potential equity raise or note tranche draw — overhang risk but also resolves cash runway question.
Key risks
- · Dilution risk: with FCF of -$24M and only ~$46M cash against $58M debt, an equity raise within 12-18 months is plausible and would pressure the stock.
- · Partner FDA setback or trial failure at a top biologics customer (PTC, uniQure, others) would unwind the drug-delivery thesis.
- · Covenant breach under the TPC note facility if revenue or burn miss plan.
- · Failure to scale gross margins above the ~62% level toward operating leverage breakeven.
- · Reimbursement headwinds for ClearPoint or IRRAflow procedures suppressing hospital adoption.
- · Continued revenue misses (as in Q1 2026) eroding the growth narrative that supports the 13x P/S multiple.
What to watch
- · Q2 2026 earnings on 2026-08-11 — revenue trajectory, IRRAS contribution, cash burn, guidance.
- · Cash runway commentary and any new debt/equity issuance.
- · Updates on biologics partner trials (uniQure, PTC, and other late-stage gene therapy programs).
- · Technical levels: 52-week high $30.10 as resistance; $8.27 low and ~$13-14 prior consolidation as downside support.
- · Short interest trend — 16.4% float short, 7.83 days to cover; covering activity on positive news.
- · Any IRRAflow indication-expansion FDA filings or clearances.
Key metrics
Price target rationale
Base $20 applies ~12x P/S to ~$50M forward revenue (FY2026E with IRRAS contribution), in line with peer high-growth medtech. Bull $30 (matches street high) assumes additional partner FDA approval and short squeeze drives multiple expansion to ~15x sales. Bear $10 reflects a dilutive raise and/or partner trial setback compressing multiple to ~6x sales near the 52-week low of $8.27.
On Wall Street's view (mixed): The $22 mean target (24% upside) is reasonable given the partner FDA momentum and growth rate, but with only 3 analysts covering and the stock having just spiked 33%, the consensus likely lags the new price; the $16 low target is now below spot, suggesting the street itself is divided.
Latest filing (10-K)
ClearPoint Neuro is a pre-profitability neurosurgery platform company that just bolted on IRRAflow neurocritical care via the IRRAS acquisition, betting that a combined disposables-driven installed base across MRI-guided surgery, OR navigation, laser ablation, and intracranial fluid management will eventually scale into profitability while its gene therapy drug delivery partnerships represent a high-optionality but partner-dependent upside.
ClearPoint Neuro (CLPT) is a commercial-stage medical device company focused on minimally invasive neurosurgery. It sells the ClearPoint MRI-guided navigation platform (hardware, disposables, software) for procedures like deep brain stimulation, laser ablation, and drug delivery into the brain, plus consulting/preclinical services to pharma companies developing brain-targeted gene and cell therapies. In November 2025, it acquired IRRAS Holdings to add the IRRAflow active intracranial fluid management system, expanding into neurocritical care. Revenue comes from capital equipment placements, high-margin recurring disposable sales, service contracts, and biologics/drug delivery services and license fees.
What the news says · bullish
The dominant storyline for CLPT in mid-June 2026 is a sharp single-day surge (~34%) driven by a partner's FDA approval plan — likely uniQure — which catalyzed significant positive momentum for ClearPoint as a drug-delivery platform beneficiary. However, this spike sits against a backdrop of persistent fundamental weakness: the stock had been down sharply earlier in the year, Q4 2025 and Q1 2026 earnings both showed losses with Q1 missing revenue estimates, and analysts had previously cut valuations citing FDA risks. Insider share sales for tax withholding are minor but add a slight cautionary note. The net picture is a stock with real catalyst-driven upside tied to its partner ecosystem, but underlying financials and prior FDA-related headwinds mean the rally may be fragile and event-dependent rather than fundamentals-driven.
This analysis is from Jun 17, 2026. Markets move. Get the current read on CLPT and generate fresh AI research on any ticker.
Every call we make is tracked publicly against what the stock actually did. See the track record →
One free AI report every day. No card required.